At the time of writing, SOPHiA Genetics SA [SOPH] stock is trading at $5.19, up 14.32%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SOPH shares have gain 25.97% over the last week, with a monthly amount glided 16.63%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
SOPHiA Genetics SA [NASDAQ: SOPH] stock has seen the most recent analyst activity on December 18, 2024, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $11. Previously, Morgan Stanley downgraded its rating to Equal-Weight on August 07, 2024, and dropped its price target to $5. On June 27, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $6 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $8 on November 29, 2023. BTIG Research started tracking with a Buy rating for this stock on January 03, 2023, and assigned it a price target of $6. In a note dated November 23, 2022, Credit Suisse initiated an Neutral rating and provided a target price of $2 on this stock.
For the past year, the stock price of SOPHiA Genetics SA fluctuated between $2.58 and $4.92. Currently, Wall Street analysts expect the stock to reach $5.33 within the next 12 months. SOPHiA Genetics SA [NASDAQ: SOPH] shares were valued at $5.19 at the most recent close of the market. An investor can expect a potential return of 2.7% based on the average SOPH price forecast.
Analyzing the SOPH fundamentals
According to SOPHiA Genetics SA [NASDAQ:SOPH], the company’s sales were 69.69M for trailing twelve months, which represents an 15.91% jump. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.97%, Pretax Profit Margin comes in at -1.02%, and Net Profit Margin reading is -1.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.79 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.73 points at the first support level, and at 4.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.48, and for the 2nd resistance point, it is at 5.76.
Ratios To Look Out For
It is important to note that SOPHiA Genetics SA [NASDAQ:SOPH] has a current ratio of 3.39. Also, the Quick Ratio is 3.21, while the Cash Ratio stands at 2.75. Considering the valuation of this stock, the price to sales ratio is 5.03, the price to book ratio is 4.57.
Transactions by insiders
Recent insider trading involved PHILIPPE MENU, Officer, that happened on Oct 30 ’25 when 1628.0 shares were purchased. Officer, PHILIPPE MENU completed a deal on Oct 20 ’25 to buy 1286.0 shares. Meanwhile, Officer MANUELA VALENTE bought 3866.0 shares on Oct 03 ’25.
